- Home
- SYRE vs VNO Comparison
SYRE vs VNO Comparison
Compare SYRE & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | VNO |
|---|---|---|
| Founded | 2013 | 1946 |
| Country | United States | United States |
| Employees | 112 | 3145 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.7B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | SYRE | VNO |
|---|---|---|
| Price | $73.58 | $32.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | ★ $85.08 | $33.00 |
| AVG Volume (30 Days) | 927.8K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | ★ N/A | $7.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.93 | $24.57 |
| 52 Week High | $78.80 | $43.37 |
Technical Indicators
Market Signals| Indicator | SYRE | VNO |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 60.81 |
| Support Level | $67.18 | $28.48 |
| Resistance Level | $76.16 | $32.73 |
| Average True Range (ATR) | 4.12 | 1.02 |
| MACD | -0.97 | -0.03 |
| Stochastic Oscillator | 62.77 | 84.12 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About VNO Vornado Realty Trust
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.